Chemours Q3 2023 Earnings Report
Key Takeaways
Chemours reported Q3 2023 results with net sales of $1.5 billion, a net income of $20 million (EPS of $0.13), and an adjusted EBITDA of $247 million. The company launched the TT Transformation Plan to drive approximately $100 million in run-rate cost savings starting in 2024 and completed the sale of the Glycolic Acid business for $138 million. Due to a weaker demand outlook, the full-year adjusted EBITDA guidance was lowered by 8% at the midpoint.
Net sales reached $1.5 billion.
Net income was reported at $20 million, with an EPS of $0.13.
Adjusted EBITDA stood at $247 million, and adjusted free cash flow was $81 million.
The TT Transformation Plan was launched, targeting approximately $100 million in run-rate cost savings from 2024.
Chemours
Chemours
Chemours Revenue by Segment
Forward Guidance
The Company is updating its full year 2023 Adjusted EBITDA and Adjusted Free Cash Flow guidance. The Company now expects full year 2023 Adjusted EBITDA to be within the range of $1.025 to $1.075 billion and Adjusted Free Cash Flow of greater than $225 million, inclusive of approximately $400 million of capital expenditures which remains unchanged.
Positive Outlook
- Committed to five strategic priorities.
- Increased focus on cost reduction activities through the TT Transformation Plan.
- Taken decisive steps to improve earnings in TT segment.
- Continue to invest in sustainability-driven growth for TSS and APM's Performance Solutions portfolio.
- Ensure prudent capital allocation and liquidity management.
Challenges Ahead
- Weaker demand outlook.
- Weaker global macroeconomic environment primarily impacting TT segment.
- Macro-driven weakness in Advanced Materials APM portfolio.
- Continued demand weakness throughout the year for products in the Advanced Materials portfolio serving economically sensitive end-markets.
- Continued elevated input costs.
Revenue & Expenses
Visualization of income flow from segment revenue to net income